title: Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
abstract: OBJECTIVE
  To investigate the role of MCP-1-2518, stromal cell-derived factor-1 (SDF-1)-G801A and chemokine receptors CCR5-Delta32, CCR5-59 029, and CCR2-64I gene polymorphisms in transitional cell carcinoma of the bladder in Mexican Mestizo patients.
  
  
  METHODS
  Forty-seven unrelated consecutive patients with non-muscle-invasive transitional cell carcinoma (TCC) and 126 unrelated healthy individuals were studied. Genomic extraction was carried out from complete blood samples using the salting out method. The PCR-RFLP method was used to amplify the following polymorphisms: MCP-1-2518, SDF-1-G801A, CCR5-Delta32, CCR5-59 029, and CCR2-64I.
  
  
  RESULTS
  The patients were divided according to low, intermediate, and high risk of progression and treated accordingly with surveillance or immunotherapy with BCG. SDF-1-G801A, CCR5-Delta32, CCR5-59 029, and CCR2-64I polymorphisms were not associated with the genetic susceptibility to non-muscle-invasive TCC of the bladder in Mexican patients. The distribution of AA, AG, and GG genotypes of MCP-1-2518 was significantly different in bladder cancer patients compared with controls (P = .006). There was a significant decrease both in the frequency of the G mutant allele (P = .021, OR = 1.752; C 95% CI 1.088-2.828) and in the GG genotype (P = .001, OR = 6.097 95% CI 1.885-19.570) in TCC patients, compared with controls.
  
  
  CONCLUSIONS
  This preliminary study shows that MCP-1 polymorphism is associated with TCC.
authors: Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
authors: Luis Gabriel
authors: LG
authors: Vázquez-Lavista
authors: Guadalupe
authors: G
authors: Lima
authors: Fernando
authors: F
authors: Gabilondo
authors: Luis
authors: L
authors: Llorente
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D001500:BCG Vaccine / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000235:genetics*; D018932:Chemokine CCL2 / Q000235:genetics*; D054377:Chemokine CXCL12 / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D054390:Receptors, CCR2 / Q000235:genetics; D019713:Receptors, CCR5 / Q000235:genetics; D019707:Receptors, Chemokine / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics*; D055815:Young Adult
chemical_list: D001500:BCG Vaccine; D018932:Chemokine CCL2; D054377:Chemokine CXCL12; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine